Netherlands-based Staten Biotechnology B.V. and Denmark-based Novo Nordisk A/S have entered into a collaboration agreement to co-develop Staten’s preclinical dyslipidemia candidate STT-5058 (ARGX-116).  Deal terms include Staten’s ability to receive upfront fees,...